The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / SSRIs Act Centrally to Cause Bone Loss

SSRIs Act Centrally to Cause Bone Loss

October 31, 2016 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

dreamstime_bonejoint_500x270Selective serotonin-reuptake inhibitors (SSRIs) can cause bone loss, especially if treatment lasts for more than a year. Maria Jose Ortuño, PhD, a postdoctoral fellow at Columbia University in New York, and colleagues sought to better understand the cellular basis underlying the time-dependent effect of SSRIs on bone. To do this, they used bone histomorphometry to examine bone mass accrual in mice treated with fluoxetine (Flx). The researchers published their descriptions of how SSRIs affect bone remodeling on Sept. 5 in Nature Medicine.1 They found that Flx had two distinct effects that shifted over time. The effects could be characterized as those associated with shorter-term use (increased bone mass) and those associated with longer-term use (decreased bone mass).

You Might Also Like
  • Th17 May Contribute to Bone Destruction by Modifying Osteoclasts
  • Bone Loss Common in Suspected Spondyloarthritis
  • The Gut Microbiome Influences Postmenopausal Bone Loss
Also By This Author
  • Human RNAi Therapy Jumps Hurdle

To better understand the shorter-term effects, the investigators treated primary osteoclast cultures with SSRIs and noted a decrease in the number of differentiated osteoclasts. Specifically, Flx inhibited the fusion of mononuclear cells that was a required step in the formation of mature, functional osteoclasts. The effect appeared to be independent of serotonin reuptake by the 5-hydroxytryptamine transporter (5HTT). Instead, treatment of cell cultures with Flx directly resulted in decreased expression of the transcription-factor-encoding oncogene Fos, as well as the downstream target of Fos, c-Fos. Likewise, the decrease in Fos expression did not result from signaling through the direct receptor activator of nuclear factor kappa-B ligand (RANKL), but instead appeared to be the result of direct impairment of the Ca2+-calmodulin-CREB-Nfatc1 signaling cascade that is required for the differentiation and function of osteoclasts. All told, the direct effect of Flx on osteoclast formation could explain the higher bone mass observed in mice following a three-week treatment with Flx.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators then searched for an indirect mechanism that might explain the bone loss seen after the mice had been treated for six weeks with Flx. They found that the urine concentrations of epinephrine and norepinephrine were significantly higher after six weeks of treatment with Flx as compared with three weeks of treatment. This suggested to the researchers that there might be a role for sympathetic output in the bone loss. Further experiments led them to conclude that, over time, Flx progressively increases serotonin signaling in the brain, thereby, inducing desensitization of 5-hydroxytryptamine receptor 2C (Htr2c) and increased sympathetic output. This conclusion was further reinforced by the observation that mice that lacked the gene coding for the enzyme necessary for brain serotonin synthesis (Tph2) did not experience the characteristic wild-type reduced bone-formation parameters after treatment with Flx.

Pages: 1 2 | Single Page

Filed Under: Conditions, Osteoarthritis Tagged With: bone, bone growth, bone loss, Osteoclasts, selective serotonin-reuptake inhibitors (SSRIs)

You Might Also Like:
  • Th17 May Contribute to Bone Destruction by Modifying Osteoclasts
  • Bone Loss Common in Suspected Spondyloarthritis
  • The Gut Microbiome Influences Postmenopausal Bone Loss
  • New Data May Explain the Role of Sclerostin in Bone Formation

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)